Evidence map›Paper›PMID 38714850›Full record

ArticleCancer gene therapy2024

TRIM58 downregulation maintains stemness via MYH9-GRK3-YAP axis activation in triple-negative breast cancer stem cells.

Xujun Li, Jing Jiang, Qian Wu, Tianzi You, Fan Yang

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Xujun Li *Department of Oncology, Ningbo No.2 Hospital, Ningbo, Zhejiang, PR China.
Jing Jiang *Department of Oncology, Ningbo No.2 Hospital, Ningbo, Zhejiang, PR China.
Qian WuDepartment of Breast Surgery, Ningbo No.2 Hospital, Ningbo, Zhejiang, PR China.
Tianzi YouTraditional Chinese Medicine Hospital of Ninghai County, Ningbo, Zhejiang, PR China.
Fan YangDepartment of Oncology, Ningbo No.2 Hospital, Ningbo, Zhejiang, PR China. yangfan@ucas.ac.cn.ORCID 0000-0001-7251-317X

Funding

Natural Science Foundation of Ningbo (Ningbo Natural Science Foundation) 2021J311Natural Science Foundation of Ningbo (Ningbo Natural Science Foundation) 2021J318Natural Science Foundation of Ningbo (Ningbo Natural Science Foundation) 2023J325Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) LY22H160010
6 · The paper itself

Abstract

TRIM58 is a member of the TRIM protein family, which possess with E3 ubiquitin ligase activities. Studies have revealed that low expression of TRIM58 plays key roles, has been implicated in the tumor progression of tumor formation due to its reduced expression. However, its role in regulating the stemness of breast cancer stem cells (CSCs) remains unexplored. Here, we found that TRIM58 was underexpressed in TNBC tissues and cells compared to adjacent mucosa tissue, and its downregulation was significantly associated with shorter survival. Overexpression of TRIM58 reduced the proportion of CD44 + /CD24- cells, upregulated differentiation genes, and inhibited stemness-related gene expression in TNBC CSCs. In vitro and in vivo experiments revealed that TRIM58 overexpression in CSCs suppressed tumor sphere formation and tumorigenic capacity. Co-IP results indicated direct interaction between TRIM58 and MYH9, with TRIM58 inducing MYH9 degradation via ubiquitination in differentiated cells. Label-free quantitative proteomics identified GRK3 and Hippo-YAP as downstream targets and signaling pathways of MYH9. TIMER database analysis, immunohistochemistry, western blotting, DNA-protein pulldown experiments, and dual luciferase reporter assays demonstrated that MYH9 regulated GRK3 transcriptional activation in CSCs. In conclusion, elevated TRIM58 expression in CSCs downregulates MYH9 protein levels by promoting ubiquitin-mediated degradation, thereby inhibiting downstream GRK3 transcription, inactivating the YAP stemness pathway, and ultimately promoting CSC differentiation.

Indexed as

Down-RegulationMyosin Heavy ChainsNeoplastic Stem CellsTriple Negative Breast NeoplasmsAdaptor Proteins, Signal TransducingAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMiceSignal TransductionTranscription FactorsTripartite Motif ProteinsUbiquitin-Protein LigasesYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingMYH9 protein, humanMyosin Heavy ChainsTranscription FactorsTripartite Motif ProteinsUbiquitin-Protein LigasesYAP1 protein, humanYAP-Signaling Proteins

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.